Maine Psilocybin Guide 2026: Law, Research & What Operators Need to Know

LD 1034: Maine's Psilocybin Decriminalization Effort

LD 1034, formally titled "An Act to Decriminalize Personal Possession of Therapeutic Amounts of Psilocybin for Adults," was introduced by Rep. Grayson Lookner (D-Portland) with bipartisan co-sponsors including Sens. Donna Bailey (D-York) and Craig Hickman (D-Kennebec) and Reps. David Boyer (R-Poland), Quentin Chapman (R-Auburn), and John Eder (R-Waterboro).

What the Bill Would Have Done

LD 1034 was a decriminalization measure, not a legalization or commercialization bill. It would have removed psilocybin from Maine's Schedule X drug classification, exempting adults 21 and older from criminal penalties for possessing one ounce or less of psilocybin mushrooms. No sales, no dispensaries, no therapeutic services framework — just the removal of criminal penalties for personal possession.

The Vote

The bill passed the House 70-69 on June 2, 2025. It passed the Senate 17-16 on June 3, 2025. Both chambers approved it by a single vote — the narrowest possible margin in both cases.

Then, on June 4, during what should have been the final enactment vote, House Majority Leader Matt Moonen (D) motioned to table the bill at the request of lead sponsor Rep. Lookner. The House voted 74-72 to table on reconsideration. The Senate deadlocked 16-16 on a subsequent vote. LD 1034 was effectively killed.

Why It Was Pulled

Opposition came from multiple corners. The Maine Department of Public Safety testified against the bill, with Maine Drug Enforcement Agency Commander Scott Pelletier noting that agents had seized over 4.5 pounds of psilocybin since January 2024 — largely during investigations of mid- and high-level traffickers distributing psilocybin alongside fentanyl, methamphetamine, and cocaine. The Maine Chiefs of Police Association opposed the bill. The Maine CDC took a cautious position, stating that while limited research shows psilocybin can be beneficial in clinical settings, the agency opposed decriminalizing possession without licensed healthcare provider oversight.

Governor Janet Mills (D), a former prosecutor, did not publicly support the bill, and concerns about a potential veto shaped the legislative dynamics in the final hours.

Current Status

LD 1034 is dead. It did not become law. Psilocybin possession in Maine carries the same criminal penalties today as it did before the bill was introduced. The bill's most enduring legacy is the study commission it created before being tabled — a research body that is now doing the substantive work that LD 1034 itself did not accomplish.

The LD 1034 Commission: What's Being Studied

Before LD 1034 was tabled, the Legislature amended it to establish the Commission to Study Pathways for Creating a Psilocybin Services Program in Maine. The commission survived the death of the underlying bill and is now working toward a November 2026 report.

Commission Mandate

The commission is tasked with producing a complete analysis of what it would take for Maine to establish a legal, regulated framework for therapeutic psilocybin use. Its required work includes:

• Reviewing available medical, psychological, and scientific studies on psilocybin for mental health disorders and end-of-life psychological distress
• Reviewing how other states — particularly Oregon and Colorado — have established legal frameworks for therapeutic psilocybin
• Reviewing previously proposed Maine legislation on psychedelic therapeutic frameworks
• Determining what steps Maine would need to take to create and maintain a legal psilocybin services program
• Developing a long-term strategic plan for a psilocybin services program that is safe, accessible, and affordable
• Identifying populations for whom psilocybin services may be appropriate

What the Commission Is Not Doing

The commission is a study body. It has no authority to create a psilocybin program, issue licenses, or change Maine law. Its output is a report with findings and recommended legislation. Whether the Legislature acts on those recommendations in 2027 is a separate political question.

Timeline

The commission must submit its report — including findings, recommendations, and any proposed legislation — by November 4, 2026. The report goes to three legislative committees: Criminal Justice and Public Safety, Veterans and Legal Affairs, and Health and Human Services. Based on those recommendations, the 133rd Legislature could introduce psilocybin legislation as early as the 2027 session.

How Other States Handle Psilocybin

Maine's commission will look closely at the two states that have moved furthest: Oregon and Colorado. Understanding their approaches clarifies the range of options Maine's Legislature might eventually consider.

Oregon: Measure 109 and the Psilocybin Services Model

Oregon voters approved Measure 109 in November 2020, creating a state-regulated psilocybin therapy program. The Oregon Health Authority licenses service center operators, psilocybin facilitators, and psilocybin manufacturers and laboratories. Adults 21 and older can access psilocybin services at licensed centers under the supervision of a licensed facilitator — but they cannot purchase psilocybin to take home. The program is therapeutic access without full retail legalization.

Oregon's program allows local governments to opt out of hosting service centers by a majority vote, which has limited access in some counties. As of early 2026, service centers are operating in several Oregon communities, with more applications pending. The program's core distinction from cannabis: it is access-only, not purchase-and-possess.

Colorado: Proposition 122 and Natural Psychedelics

Colorado voters approved Proposition 122 in November 2022, taking a broader approach than Oregon. The measure decriminalized personal possession, use, and cultivation of psilocybin mushrooms, mescaline, DMT, ibogaine, and psilocin for adults 21 and older. It also established a regulated "healing center" framework similar to Oregon's facilitated access model. Colorado's approach explicitly covers multiple natural psychedelics, not just psilocybin, and allows personal cultivation also supervised services. Local governments can also opt out of hosting healing centers.

Why the Commission's Work Matters

Both Oregon and Colorado programs went through multi-year rulemaking periods after voter approval before any licensed services began. Maine does not have a voter initiative pathway for drug policy — any program would require the Legislature to act. The commission's job is to tell lawmakers exactly what they would be enacting if they passed a psilocybin services bill, reducing the legislative risk of moving into unfamiliar territory without a plan.

Federal Action: The April 2026 Executive Order

On April 18, 2026, President Trump signed an executive order in the Oval Office directing the Food and Drug Administration to fast-track the review of psychedelic drugs, including psilocybin and ibogaine, for the treatment of mental health conditions.

What the Executive Order Does

FDA Fast-Track Review. The order instructs the FDA to expedite review of psychedelic drugs and adds three psychedelics to the National Priority Voucher pilot program — a pathway designed to dramatically reduce review timelines for substances aligned with national health priorities. FDA Commissioner Dr. Marty Makary indicated that approvals for certain substances could come "as soon as this summer."

$50 Million for Ibogaine Research. The federal government committed $50 million specifically for ibogaine research — a substance with documented promise for opioid withdrawal and PTSD treatment but also known cardiac risks. Psilocybin is included in the broader fast-track directive but is not the primary funding target.

Right to Try Pathway. The order opens a pathway for ibogaine to be administered to eligible patients under the FDA's Right to Try rule for life-threatening conditions. This applies to ibogaine specifically.

Reclassification Framework. Federal officials at the signing ceremony signaled that the reforms are intended to pave the way for reclassification after successful clinical trials. The order itself does not reschedule any substance. Psilocybin and ibogaine remain Schedule I drugs under federal law today.

What It Means for Maine

The executive order does not change psilocybin's legal status in Maine or under federal law. It accelerates the research and regulatory review timeline that could eventually support reclassification — but that process is measured in years, not months. For Maine's commission, the most significant effect is political: when the commission delivers its November 2026 report, the federal landscape will look substantially more favorable to psilocybin research than when LD 1034 was introduced in 2025.

Federal action also provides what policy researchers call "cover" — it becomes harder for state lawmakers to dismiss psilocybin as a fringe issue when the FDA is actively fast-tracking its review at the direction of a Republican president.

What Maine Cannabis Operators Need to Know

This section is direct: psilocybin and cannabis are entirely separate regulatory frameworks in Maine, and licensed cannabis operators have significant skin in the game when it comes to psilocybin policy — even if they never intend to touch the substance.

Psilocybin Is Not Cannabis

Maine's Office of Cannabis Policy licenses adult-use and medical cannabis operators under a framework governed by the Maine Marijuana Legalization Act and associated OCP rules. Psilocybin falls under Maine's controlled substances law (17-A M.R.S. § 1101 et seq.) and is enforced through law enforcement channels, not the OCP. There is no regulatory overlap. The two substances are handled by entirely different legal systems in Maine.

The License Risk

Any Maine cannabis operator who handles, stores, distributes, or sells psilocybin risks their OCP license — not just criminal exposure. OCP licensing agreements require compliance with all applicable Maine laws, and psilocybin possession is a Class D crime. A compliance action or arrest involving psilocybin at a licensed cannabis facility could result in license suspension or revocation, regardless of whether the psilocybin activity was commercially motivated or separate from the cannabis operation.

This risk applies whether or not a future psilocybin program is under consideration. Until Maine law explicitly authorizes psilocybin services through a licensed framework — which has not happened — the two industries must remain entirely separate.

How to Monitor Without Overstepping

Cannabis operators can legitimately follow psilocybin policy developments without taking any position on psilocybin products or services. Following the commission's public hearings, tracking the November 2026 report, and consulting with legal counsel about what a future psilocybin services framework might mean for business planning are all appropriate. Operators who eventually wish to explore psilocybin services — if and when a legal program exists — would likely need to do so through an entirely separate business entity under a separate license.

Timeline: What Comes Next

Setting realistic expectations matters here. Psilocybin policy moves in a different gear from cannabis — and Maine's experience with cannabis legalization is instructive. Maine voters approved adult-use cannabis in 2016. The first adult-use dispensaries didn't open until 2020. The policy infrastructure for a regulated substance market takes time to build even after political authorization.

Near-Term: Now Through November 2026

The Commission to Study Pathways for Creating a Psilocybin Services Program in Maine is doing its work. Public hearings may be scheduled. The commission will review scientific literature, study Oregon and Colorado programs, and develop a recommended framework. Federal developments — FDA voucher issuances, ibogaine trial results, any DEA rescheduling discussions — will inform the commission's thinking.

Medium-Term: 2027 Legislative Session

If the commission recommends legislation — which its mandate suggests it will — the 133rd Legislature's 2027 session is the earliest opportunity for Maine to act. Whether that legislation advances will depend on the political composition of the Legislature following the 2026 elections, the governor's position, and the strength of the commission's recommendations. A bill could pass, fail, or be amended into something much more limited than what the commission recommends.

Long-Term: Realistic Program Launch

Even if the 2027 Legislature passes a psilocybin services bill, a regulated program would require rulemaking, licensing infrastructure, and implementation time. Oregon's program took approximately three years from voter approval to first licensed services. Maine's timeline, working from a legislative authorization rather than a voter mandate, would likely be similar. A functioning Maine psilocybin services program — if it happens at all — is realistically a 2029 or later prospect.

Frequently Asked Questions

Related Guides

Explore Maine's cannabis regulatory framework and policy landscape.